The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable.
What changes if the standard account of c-cell question is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Answering the question post #3 raises rather than the one it answers.
On formulation: the licensed product is buffered and includes a preservative in the multi-dose presentation. A reconstituted research preparation matches neither, and stability claims made about the first do not carry over to the second.
The short version is the first sentence; the rest is why.
I came in to disagree and I am leaving without a disagreement.
On the "does it stop working" question: tolerance in the pharmacological sense is not what the withdrawal trials show. What they show is that the effect persists while treatment continues and reverses when it stops, which is a different finding with different implications.
C-cell question: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Worth separating two things this subcategory keeps merging: what the molecule does, which is reasonably well characterised, and what a particular vial contains, which is a documentation question and has nothing to do with pharmacology.
A guess, clearly labelled as one.
Picking up post #12: that is the part I would want checked first.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Coming back to post #14, because the follow-up matters more than the original answer.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
This follows post #16 rather than contradicting it.
Taking c-cell question seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Post #16 answers the question as asked. The question underneath it is different.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
I read post #18 twice before replying, because I had assumed the opposite.
The reason c-cell question keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown.
The claim about c-cell question upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Post #19 is the version of this I will quote in future. One addition.
The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.
If anyone has run this properly I would rather read that than my own guess.
The documentation on c-cell question is better than this thread and I say that as someone who has posted in the thread.
I had written a reply contradicting post #23 and deleted it. Here is what survived.
Appetite effects and gastrointestinal effects are frequently reported together and are not the same mechanism reported twice. Slowed gastric emptying contributes to both, but central satiety signalling accounts for effects that persist after emptying has normalised.
Confirming post #23 from a second method, which matters more than confirming it from a second person.
C-cell question: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Noted, and thank you for writing it out rather than summarising it.
My understanding of c-cell question is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.